Close

Ms Vanessa Yardley

PhD

Assistant Professor

Room
238B

LSHTM
Keppel Street
London
WC1E 7HT
United Kingdom

Tel.
0207 927 2462

1990: BSc (Hons) Biology (Parasitology), Kings College London

1991: MSc Medical Parasitology, LSHTM

2002: PhD University of London.  "Action of amphotericin B formulations on Leishmania spp. and Trypanosoma cruzi, in vitro and in vivo."

Affiliations

Faculty of Infectious and Tropical Diseases
Department of Infection Biology

Teaching

3122 'Parasitology & entomology" module co-organiser.

3133 Field Trip organiser and senior member of staff

Tutor and lecturer on various MSc programmes.

MSc Course committee member and Exam Board member - previously Chair

Supervision of PhD and MSc students for lab-based projects.

Research

Currently funded by Research Council, NGO, EU, GHIT on a variety of projects involving in vivo models of Leishmania infection, including development of improved dignostic tools, support for clinical trials, vaccine candidate evaluation and long standing drug evaluation programme.

Research Area
Clinical care
Clinical trials
Diagnostics
Drug discovery and development
Drug resistance
Parasites
Pharmacovigilance
Trypanosomes
Vaccines
Chemotherapy
Disease control
Pharmacokinetics
Protozoa
Discipline
Immunopathology
Cell biology
Molecular biology
Parasitology
Pharmacology
Disease and Health Conditions
Infectious disease
Malaria
African trypanosomiasis
Chagas Disease
Emerging Infectious Disease
Neglected Tropical Diseases (NTDs)
Skin disease
Tropical diseases
Zoonotic disease
Leishmaniasis
Human African trypanosomiasis
Region
World

Selected Publications

Drug reformulation for a neglected disease. The NANOHAT project to develop a safer more effective sleeping sickness drug.
Sanderson L; da Silva M; Sekhar GN; Brown RC; Burrell-Saward H; Fidanboylu M; Liu B; Dailey LA; Dreiss CA; Lorenz C
2021
PLoS neglected tropical diseases
Heteroaryl ether analogues of an antileishmanial 7-substituted 2-nitroimidazooxazine lead afford attenuated hERG risk: In vitro and in vivo appraisal.
Thompson AM; O'Connor PD; Marshall AJ; Yardley V; Maes L; Gupta S; Launay D; Braillard S; Chatelain E; Wan B
2021
European journal of medicinal chemistry
Novel Linker Variants of Antileishmanial/Antitubercular 7-Substituted 2-Nitroimidazooxazines Offer Enhanced Solubility.
Thompson AM; O'Connor PD; Yardley V; Maes L; Launay D; Braillard S; Chatelain E; Wan B; Franzblau SG; Ma Z
2021
ACS medicinal chemistry letters
Novel 2D and 3D Assays to Determine the Activity of Anti-Leishmanial Drugs.
O'Keeffe A; Hale C; Cotton JA; Yardley V; Gupta K; Ananthanarayanan A; Murdan S; Croft SL
2020
Microorganisms
Activity of Amphotericin B-Loaded Chitosan Nanoparticles against Experimental Cutaneous Leishmaniasis.
Riezk A; Van Bocxlaer K; Yardley V; Murdan S; Croft SL
2020
Molecules
An efficient and novel technology for the extraction of parasite genomic DNA from whole blood or culture.
Clark DJ; Moore CM; Flanagan M; Bocxlaer KV; Piperaki E-T; Yardley V; Croft SL; Tyson J; Whitehouse SP; O'Halloran J
2019
BioTechniques
Activity of Chitosan and Its Derivatives against Leishmania major and Leishmania mexicana In Vitro.
Riezk A; Raynes JG; Yardley V; Murdan S; Croft SL
2019
Antimicrobial agents and chemotherapy
See more Publications